Masahiro Seike

Title: Masahiro Seike: Innovator in Cancer Prognosis

Introduction

Masahiro Seike is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer research, particularly in the prognosis of adenocarcinoma. His innovative methods have the potential to improve patient outcomes and enhance therapeutic strategies.

Latest Patents

Masahiro Seike holds a patent for "Methods of determining the prognosis of an adenocarcinoma." This patent outlines methods for determining the prognosis of a subject with adenocarcinoma in organs such as the lung. The methods involve quantitating the expression of various cytokines, including IL-1a, IL-1b, IL-2, IL-8, IL-10, IL-12, IL-15, IFN-γ, and TNF-a in both adenocarcinoma and non-cancerous tissue. The altered expression of these cytokines compared to control samples helps determine the prognosis for the subject. Additionally, the patent includes methods for assessing the effectiveness of therapeutic agents as anti-cancer treatments.

Career Highlights

Throughout his career, Masahiro Seike has worked with prestigious organizations, including the National Institutes of Health, a component of the U.S. Department of Health & Human Services. His work has focused on advancing the understanding of cancer prognosis and treatment.

Collaborations

Masahiro Seike has collaborated with esteemed colleagues such as Curtis C. Harris and Xin Wei Wang. Their joint efforts have contributed to the development of innovative cancer research methodologies.

Conclusion

Masahiro Seike's contributions to cancer prognosis through his patented methods highlight his role as an influential inventor in the medical field. His work continues to pave the way for advancements in cancer treatment and patient care.